【Company Research】Xinyi Solar (968 HK) – Price war brewing |
【Company Research】CITIC Securities (6030 HK) – RMB 28bn A+H rights issue to beef up capital base |
【Company Research】Simcere Pharmaceutical Group (2096 HK) – FDA approved trilaciclib for chemotherapy-induced myelosuppression |
【Company Research】JNBY Design (3306 HK) – Speedy recovery and ambitious long-term goal |
【Company Research】NWS Holdings (659 HK) – Recovery on track post COVID-19 |
【Company Research】CG Service (6098 HK) – Acquisition of Languang: more positive on lower-than-expected purchase price |
【Company Research】Bilibili (BILI US) – Guiding 400mn MAU in FY23E |
【Company Research】Kintor Pharmaceutical (9939 HK) – Enrollment completed for proxalutamide for hospitalized COVID-19 patients in Brazil |
【Company Research】WH Group (288 HK) – Recovery led by US market in 2021E |
【Company Research】Hong Kong Exchange & Clearing (388 HK) – Stamp duty hike impact not significant; current valuation largely reflects strong ADT trend |